• Carboplatin: From DNA Damage to Translation

  2026-09-14

  Carboplatin is more than a cytotoxic benchmark: it is a translational probe for linking DNA damage, replication stress, repair capacity, and tumor-model context. This article outlines how to build better ovarian and lung cancer studies, interpret combination data, and move from product-level potency claims toward decision-ready preclinical evidence.

• Lamotrigine BBB Assay Design for CNS Research

  2026-09-14

  Lamotrigine is examined here through a translational BBB assay framework rather than a conventional mechanism summary. Learn how bidirectional transport, efflux, recovery, and lysosomal trapping controls can improve interpretation of CNS, epilepsy, and sodium-channel research.

• A1 Fluorinated CXCR4 Inhibitor in Colorectal Cancer

  2026-09-13

  Khorramdelazad et al. evaluate A1, a fluorinated CXCR4 inhibitor, through molecular simulation, CT-26 cell assays, and a BALB/c colorectal cancer model. A1 showed more favorable calculated receptor binding and stronger preclinical effects than AMD3100, including reduced tumor growth, migration, regulatory T-cell infiltration, and immunosuppressive signaling.

• CA800-PR Targets Progesterone Receptor in HR+ Breast Cancer

  2026-09-12

  The reference study introduces CA800-PR, a hydrophilic heptamethine cyanine dye designed to combine tumor targeting, near-infrared imaging, and treatment in hormone receptor-positive breast cancer. In MCF-7 cells and xenograft tumors, the dye was associated with Golgi fragmentation, selective suppression of progesterone receptor protein expression, apoptosis, cytokine production, and increased antitumor macrophage markers.

• Valemetostat: Reliable EZH1/2 Assay Design

  2026-09-11

  A scenario-driven guide to using Valemetostat (SKU BA4816) in cell viability, proliferation, and cytotoxicity workflows. It connects EZH2 biochemical potency, formulation constraints, assay controls, and vendor-selection criteria to improve interpretation and reproducibility in lymphoma research.

• Procainamide Hydrochloride: An Assay-First Guide

  2026-09-11

  Procainamide Hydrochloride is more than a cardiac sodium channel blocker: it is a versatile research probe spanning Nav1.5 electrophysiology, immune signaling, epigenetic regulation, and drug-delivery studies. This assay-first guide explains how to separate these biological readouts and interpret the influential cisplatin–liposome research without overextending its conclusions.

• Dovitinib: Chamber-Specific Assay Design

  2026-09-10

  Dovitinib (TKI-258) combines broad RTK inhibition with a useful framework for dissecting pathway-dependent apoptosis in cancer models. This article adds a distinct assay-design perspective by connecting oncology pharmacology with chamber-specific human stem cell-derived cardiomyocytes while clearly separating established evidence from testable applications.

• Laminin (925-933) Workflow for Adhesion Assays

  2026-09-10

  Laminin (925-933) is a defined Laminin B1 chain peptide for separating peptide-mediated cell attachment and chemotaxis from the broader complexity of full-length laminin. This guide covers stock preparation, adhesion and migration assay setup, controls, and limitations; it is intended for research workflows only, not diagnostic, therapeutic, or clinical use.

• JNJ-10198409: A Systems-Level PDGF Assay Strategy

  2026-09-09

  JNJ-10198409 is a platelet-derived growth factor receptor inhibitor suited to mechanistic studies of ATP-competitive kinase blockade, proliferation, and angiogenesis. This article develops an assay strategy that connects PDGF-BB target engagement with the stage-dependent signaling logic revealed by recent host–pathogen research.

• Ferroptosis Signature Identifies Atorvastatin in HCC

  2026-09-09

  A 2025 study integrated ferroptosis-related transcriptomics, survival modeling, Connectivity Map screening, and laboratory validation to develop a four-gene prognostic signature for hepatocellular carcinoma. The analysis nominated Atorvastatin as a potential ferroptosis-inducing treatment candidate, although the evidence remains preclinical and requires independent validation.

• Miltefosine Activates ERK to Restore Neutrophils

  2026-09-08

  A 2025 study identifies Miltefosine as a potential leukopenia intervention that promotes neutrophil differentiation through Ras/MEK/ERK signaling. Using leukemia-cell models, an irradiation-induced mouse model, transcriptomics, network pharmacology, molecular docking, and pathway inhibition, the authors connect Miltefosine exposure with improved myelopoiesis and neutrophil function.

• Radicicol: From Hsp90 Biology to Translational Design

  2026-09-08

  Radicicol is more than an Hsp90 inhibitor: it is a mechanistic probe for testing how chaperone dependence, kinase signaling, apoptosis, adipogenesis, and inflammation intersect. This thought-leadership article connects Radicicol pharmacology with new evidence on HSP90-dependent antigen cross-presentation and translates those insights into assay and study-design guidance.

• Trichostatin A (TSA): Reliable Cell Assays

  2026-09-07

  A scenario-driven guide to using Trichostatin A (TSA), SKU A8183, in viability, proliferation, and cytotoxicity workflows. It connects HDAC biology with solvent control, dose-response design, endpoint interpretation, and practical product selection.

• Protease Inhibitor Cocktail for Phospho-Protein Workflows

  2026-09-07

  Protect labile proteins during cell and tissue lysis with an EDTA-free, broad-spectrum formulation suited to Western blotting, co-immunoprecipitation, kinase assays, and signaling studies. This workflow connects protease inhibition in cell lysates with the IκBα–NF-κB experiments reported in p53-mutant lymphoma research, while addressing DMSO, phosphorylation, and sample-quality pitfalls.

• BHPF–GPER Binding and Neuroblastoma Apoptosis

  2026-09-05

  The 2024 reference study identifies fluorene-9-bisphenol (BHPF) as a direct functional inhibitor of GPER, rather than simply an unconventional estrogen-active contaminant. By combining molecular dynamics, receptor perturbation, mutagenesis, calcium signaling, cytotoxicity, and gene-expression assays, the authors connect two receptor residues with BHPF recognition and impaired GPER signaling.

8532 records 1/569 page Next 12345 下5页 Last page